Drug Trial Radar · NCT01846273
Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT)
Last checked: Nov 20, 2026Latest source record: Jun 7, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
321
Actual
Start
Aug 7, 2013
Primary completion
Mar 11, 2016
Study completion Mar 2, 2017
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- May 3, 2013
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study compared the effect of ranibizumab administered as monotherapy versus ranibizumab administered in combination with verteporfin photodynamic therapy (PDT) on visual acuity in patients with symptomatic macular polypoidal choroidal vasculopathy (PCV). The results of this study provided long-term safety and efficacy data used to generate further guidance on the management of patients with PCV.
Conditions
- Age-related Macular Degeneration
- Polypoidal Choroidal Vasculopathy
Interventions
RanibizumabDrug
Intravitreal injection of 0.5 mg ranibizumab
Verteporfin PDTDrug
Infusion of 30 ml verteporfin in 5% dextrose solution followed by 83 sec of laser light (50J/cm2; 600mW/cm2; 689 nm)
Sham PDTDrug
Infusion of 30 ml 5% dextrose solution followed by 83 sec of laser light (50J/cm2; 600mW/cm2; 689 nm)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12 - Study EyeTime frame: Baseline, Month 12
- Number of Patients With Complete Polyp Regression From Baseline at Month 12 - Study EyeTime frame: Baseline, Month 12
Locations
41 sites in 7 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Hong Kong, Hong Kong
Novartis Investigative Site
Chiba, Japan
Novartis Investigative Site
Nagoya, Aichi-ken, Japan
Novartis Investigative Site
Nagoya, Aichi-ken, Japan
Novartis Investigative Site
Fukuoka, Fukuoka, Japan
Novartis Investigative Site
Fukushima, Fukushima, Japan
Novartis Investigative Site
Maebashi, Gunma, Japan
Novartis Investigative Site
Amagasaki, Hyōgo, Japan
Novartis Investigative Site
Kobe, Hyōgo, Japan
Novartis Investigative Site
Kobe, Hyōgo, Japan
Novartis Investigative Site
Inashiki-gun, Ibaraki, Japan
Novartis Investigative Site
Kita-gun, Kagawa-ken, Japan
Novartis Investigative Site
Sakyo-ku, Kyoto, Japan
Novartis Investigative Site
Tsu, Mie-ken, Japan
Novartis Investigative Site
Okayama, Okayama-ken, Japan
Novartis Investigative Site
Hirakata, Osaka, Japan
Novartis Investigative Site
Osaka, Osaka, Japan
Novartis Investigative Site
Osaka, Osaka, Japan
Novartis Investigative Site
Ohtsu-city, Shiga, Japan
Novartis Investigative Site
Bunkyo Ku, Tokyo, Japan
Novartis Investigative Site
Chiyoda-ku, Tokyo, Japan
Novartis Investigative Site
Mitaka, Tokyo, Japan
Novartis Investigative Site
Shinjuku Ku, Tokyo, Japan
Novartis Investigative Site
Batu Caves, Selangor, Malaysia
Novartis Investigative Site
Petaling Jaya, Selangor, Malaysia
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seongnam-si, Gyeonggi-do, South Korea
Novartis Investigative Site
Seoul, Korea, South Korea
Novartis Investigative Site
Seoul, Seocho-gu, South Korea
Novartis Investigative Site
Changhua, Taiwan
Novartis Investigative Site
Kaohsiung City, Taiwan
Novartis Investigative Site
Taipei, Taiwan
Novartis Investigative Site
Taipei, Taiwan
Novartis Investigative Site
Taoyuan, Taiwan
Novartis Investigative Site
Taipei, Taiwan, ROC, Taiwan
Novartis Investigative Site
Bangkok, Thailand
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.